MCID: CLR030
MIFTS: 49

Clear Cell Renal Cell Carcinoma

Categories: Rare diseases, Nephrological diseases, Cancer diseases

Aliases & Classifications for Clear Cell Renal Cell Carcinoma

MalaCards integrated aliases for Clear Cell Renal Cell Carcinoma:

Name: Clear Cell Renal Cell Carcinoma 12 53 59
Clear-Cell Metastatic Renal Cell Carcinoma 12 53 73
Clear Cell Carcinoma of Kidney 12 29 6
Renal Clear Cell Carcinoma 12 55 15
Conventional Renal Cell Carcinoma 12 73
Clear Cell Renal Cell Adenocarcinoma 59
Conventional Renal Cell Carcinoma 12
Clear Cell Kidney Carcinoma 12
Cystic-Multilocular Variant 53
Clear Cell Renal Carcinoma 59
Clear Cell Rcc 53
Ccrcc 59

Classifications:

Orphanet: 59  
Rare renal diseases


External Ids:

Disease Ontology 12 DOID:4467
MeSH 44 D002292
NCIt 50 C4033
Orphanet 59 ORPHA319276
UMLS via Orphanet 74 C0279702
ICD10 via Orphanet 34 C64

Summaries for Clear Cell Renal Cell Carcinoma

NIH Rare Diseases : 53 Clear cell renal cell carcinoma is a cancer of the kidney.  The name "clear cell" refers to the appearance of the cancer cells when viewed with a microscope.  Clear cell renal cell carcinoma occurs when cells in the kidney quickly increase in number, creating a lump (mass).  Though the exact cause of clear cell renal cell carcinoma is unknown, smoking, the excessive use of certain medications, and several genetic predisposition conditions (such as von Hippel Lindau syndrome) may contribute to the development of this type of cancer.  Treatment often begins with surgery to remove as much of the cancer as possible, and may be followed by radiation therapy, chemotherapy, biological therapy, or targeted therapy.

MalaCards based summary : Clear Cell Renal Cell Carcinoma, also known as clear-cell metastatic renal cell carcinoma, is related to renal cell carcinoma, nonpapillary and clear cell papillary renal cell carcinoma, and has symptoms including flank pain An important gene associated with Clear Cell Renal Cell Carcinoma is PBRM1 (Polybromo 1). The drugs Sunitinib and Bevacizumab have been mentioned in the context of this disorder. Affiliated tissues include kidney, endothelial and t cells.

Disease Ontology : 12 A renal cell carcinoma that has material basis in cells that appear very pale or clear when examined under microscope.

Wikipedia : 76 The Clear Cell Renal Cell Carcinoma (CCRCC) is a type of renal cell... more...

Related Diseases for Clear Cell Renal Cell Carcinoma

Diseases related to Clear Cell Renal Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 107)
# Related Disease Score Top Affiliating Genes
1 renal cell carcinoma, nonpapillary 33.0 CYTOR HNF1A LINC00887 MALAT1 OGG1 PANDAR
2 clear cell papillary renal cell carcinoma 31.7 HNF1A PBRM1
3 kidney cancer 30.9 MALAT1 MEG3 PVT1
4 melanoma 29.6 MALAT1 MEG3 PVT1 SPRY4-IT1
5 lung cancer 29.1 ADAMTS9-AS2 CCAT2 MALAT1 MEG3 OGG1 PANDAR
6 multilocular clear cell renal cell carcinoma 12.3
7 hereditary conventional renal cell carcinoma 12.2
8 multilocular cystic renal neoplasm of low malignant potential 11.5
9 chromophobe renal cell carcinoma 11.4
10 von hippel-lindau syndrome 11.1
11 birt-hogg-dube syndrome 11.1
12 malignant glioma 10.8 CYTOR MALAT1 MEG3
13 prostate disease 10.8 MALAT1 MEG3
14 pituitary adenoma 10.8 CCAT2 MALAT1 MEG3
15 ovarian epithelial cancer 10.8 CCAT2 MALAT1 MEG3
16 intrahepatic cholangiocarcinoma 10.8 CCAT2 PBRM1 TUG1
17 vulva squamous cell carcinoma 10.7 MALAT1 MEG3
18 tongue squamous cell carcinoma 10.7 CYTOR MALAT1 MEG3
19 esophagus squamous cell carcinoma 10.6 MEG3 TUG1
20 testicular germ cell cancer 10.6 MEG3 SPRY4-IT1
21 endotheliitis 10.5
22 small cell cancer of the lung 10.5 CCAT2 MALAT1 TUG1
23 thyroid cancer, nonmedullary, 1 10.5 MALAT1 MEG3 PVT1
24 gallbladder cancer 10.5 CYTOR MALAT1 MEG3 TUG1
25 oral squamous cell carcinoma 10.4 CCAT2 MALAT1 MEG3 TUG1
26 hypoxia 10.4
27 squamous cell carcinoma 10.4 CCAT2 MALAT1 SPRY4-IT1 TUG1
28 bladder urothelial carcinoma 10.3 MALAT1 MEG3 PVT1 TUG1
29 cholangiocarcinoma 10.3 CCAT2 MALAT1 OGG1 PANDAR PBRM1 SPRY4-IT1
30 lung squamous cell carcinoma 10.3 CCAT2 MEG3 PVT1 TUG1
31 hemangioblastoma 10.3
32 myeloma, multiple 10.3 MALAT1 MEG3 PVT1 TUG1
33 glioma 10.2 CCAT2 CYTOR MALAT1 MEG3 PVT1 SPRY4-IT1
34 renal cell carcinoma, papillary, 1 10.2
35 b-cell lymphomas 10.2 MALAT1 PVT1 TUG1
36 angiomyolipoma 10.2
37 aging 10.1
38 oncocytoma 10.1
39 osteogenic sarcoma 10.1 CCAT2 MALAT1 MEG3 PANDAR PVT1 TUG1
40 type i 10.1
41 glioblastoma 10.1 CYTOR MALAT1 MEG3 TUG1
42 insulin-like growth factor i 10.1
43 body mass index quantitative trait locus 1 10.1
44 renal oncocytoma 10.1
45 hemangioma 10.0
46 hepatitis 10.0
47 hepatitis a 10.0
48 prostatitis 10.0
49 adenocarcinoma 10.0
50 adenoma 10.0

Graphical network of the top 20 diseases related to Clear Cell Renal Cell Carcinoma:



Diseases related to Clear Cell Renal Cell Carcinoma

Symptoms & Phenotypes for Clear Cell Renal Cell Carcinoma

UMLS symptoms related to Clear Cell Renal Cell Carcinoma:


flank pain

Drugs & Therapeutics for Clear Cell Renal Cell Carcinoma

Drugs for Clear Cell Renal Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 187)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 341031-54-7, 557795-19-4 5329102
2
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
3
Aldesleukin Approved Phase 4,Phase 2,Phase 1,Early Phase 1 85898-30-2, 110942-02-4
4
nivolumab Approved Phase 4,Phase 3,Phase 2,Phase 1 946414-94-4
5 Interleukin-2 Phase 4,Phase 2,Phase 1,Early Phase 1
6 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
9 Anti-HIV Agents Phase 4,Phase 2,Phase 1,Early Phase 1
10 Anti-Retroviral Agents Phase 4,Phase 2,Phase 1,Early Phase 1
11 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
12 Analgesics Phase 4,Phase 2,Phase 1,Early Phase 1
13 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 1,Early Phase 1
14 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 1,Early Phase 1
15 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Antibodies, Monoclonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18
Sorafenib Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 284461-73-0 216239 406563
19
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
20
Everolimus Approved Phase 3,Phase 2,Phase 1,Not Applicable 159351-69-6 6442177
21
Axitinib Approved, Investigational Phase 3,Phase 2,Phase 1 319460-85-0 6450551
22
Sirolimus Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 53123-88-9 5284616 6436030 46835353
23
Iodine Approved, Investigational Phase 3 7553-56-2 807
24 interferons Phase 3,Phase 2,Phase 1
25 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
26 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
27 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
28 Interferon-alpha Phase 3,Phase 2,Phase 1
29 Antifungal Agents Phase 3,Phase 2,Phase 1,Not Applicable
30 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 cadexomer iodine Phase 3
32 Micronutrients Phase 3,Phase 1,Phase 2,Not Applicable
33 Mitogens Phase 3,Phase 2,Phase 1
34 Trace Elements Phase 3,Phase 1,Phase 2,Not Applicable
35 Endothelial Growth Factors Phase 3,Phase 2,Phase 1
36 Pharmaceutical Solutions Phase 3,Phase 2,Phase 1
37 Immunoconjugates Phase 3,Phase 1
38 Immunoglobulin G Phase 3,Phase 2,Phase 1
39 Anti-Infective Agents, Local Phase 3
40 tyrosine Nutraceutical Phase 3,Phase 1,Phase 2
41
Heparin Approved, Investigational Phase 1, Phase 2 9005-49-6 772 46507594
42
Tinzaparin Approved Phase 1, Phase 2 9005-49-6, 9041-08-1 25244225
43
Dalteparin Approved Phase 1, Phase 2 9005-49-6
44
Gemcitabine Approved Phase 2 95058-81-4 60750
45
Vidarabine Approved, Investigational Phase 2,Phase 1,Not Applicable 24356-66-9 32326 21704
46
Lenograstim Approved, Investigational Phase 2,Phase 1 135968-09-1
47
Fludarabine Approved Phase 2,Phase 1,Not Applicable 21679-14-1, 75607-67-9 30751
48
Etoposide Approved Phase 2,Phase 1 33419-42-0 36462
49
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
50
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703

Interventional clinical trials:

(show top 50) (show all 216)
# Name Status NCT ID Phase Drugs
1 Interleukin-2 in Treating Patients With Metastatic Kidney Cancer Completed NCT00006864 Phase 4
2 First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma Completed NCT01521715 Phase 4 Pazopanib
3 Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therapy Active, not recruiting NCT02570789 Phase 4 patients with sunitinib or pazopanib
4 A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer Active, not recruiting NCT02982954 Phase 4 Nivolumab;Ipilimumab
5 Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma Terminated NCT00930345 Phase 4 Sunitinib (SUTENT)
6 Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody Completed NCT00606632 Phase 3 124-Iodine-cG250 (124I-cG250)
7 Zirconium-89-girentuximab PET/CT Imaging in Renal Cell Carcinoma Completed NCT02883153 Phase 2, Phase 3 Zirconium-89 girentuximab PET/CT
8 A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy Completed NCT00738530 Phase 3 Bevacizumab [Avastin];Interferon alfa 2a [Roferon];Placebo
9 TroVax Renal Immunotherapy Survival Trial Completed NCT00397345 Phase 3
10 Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer Completed NCT00087022 Phase 3
11 Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer) Completed NCT00072046 Phase 3
12 Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer Completed NCT00492258 Phase 3 sorafenib tosylate
13 Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discovery Recruiting NCT02535351 Phase 3 sunitinib or pazopanib
14 Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025) Active, not recruiting NCT01668784 Phase 3 Everolimus
15 Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery Active, not recruiting NCT01575548 Phase 3 Pazopanib Hydrochloride
16 Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer Active, not recruiting NCT01099423 Phase 3
17 Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy Active, not recruiting NCT01198158 Phase 3 Everolimus
18 S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Active, not recruiting NCT01120249 Phase 3 everolimus
19 Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients Terminated NCT01599754 Phase 3 Axitinib;Placebo
20 REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT Withdrawn NCT01762592 Phase 3 Iodine (124I) Girentuximab
21 Neoadjuvant Sunitinib Treatment for Metastatic Clear Cell Renal Cell Carcinoma (RCC) Unknown status NCT01069770 Phase 2 Sunitinib
22 1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC Unknown status NCT01791387 Phase 2 Dovitinib
23 Resection of Pulmonary Metastasis in Clear Cell Renal Cell Carcinoma +/-Adjuvant Sunitinib Therapy (SMAT) Unknown status NCT01216371 Phase 2 Sunitinib;Placebo
24 Tinzaparin in Treating Patients With Metastatic Kidney Cancer That Cannot Be Removed By Surgery Unknown status NCT00293501 Phase 1, Phase 2 tinzaparin sodium
25 Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer Unknown status NCT00301990 Phase 2
26 Sequential Therapy With Bevacizumab, RAd001 (Everolimus) and Tyrosinekinase Inhibitors (TKI) in Metastatic Renal Cell Carinoma (mRCC) Unknown status NCT01731158 Phase 2 Avastin in combination with Roferon-A;Afinitor;Sutent, Nexavar or Votrient
27 A Phase II Study of Axitinib in Patients With Metastatic Renal Cell Cancer Unsuitable for Nephrectomy Unknown status NCT01693822 Phase 2 Axitinib
28 Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA Completed NCT02607553 Phase 2 G-202
29 BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Completed NCT01034631 Phase 1, Phase 2 Everolimus;BNC105P
30 GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma Completed NCT00244764 Phase 2 GW786034;Placebo
31 A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC). Completed NCT00796757 Phase 2 bevacizumab [Avastin];interferon alfa-2a
32 Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney Completed NCT00853021 Phase 2
33 LBH589 Treatment for Refractory Clear Cell Renal Carcinoma Completed NCT00550277 Phase 2 LBH589
34 Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma Completed NCT00729053 Phase 2 IMO-2055
35 Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer Completed NCT02002312 Phase 2 Lu-177-DOTA-girentuximab
36 Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer Completed NCT00408902 Phase 2 tandutinib
37 AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib Completed NCT00467025 Phase 2 AMG 386;Sorafenib;AMG 386 placebo IV
38 Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma Completed NCT00193258 Phase 1, Phase 2 Bevacizumab;Erlotinib;Imatinib
39 Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma Completed NCT00323739 Phase 2 bevacizumab;RAD001
40 Biomarkers Before and After Nephrectomy of Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Everolimus Completed NCT01715935 Phase 2 Everolimus
41 High-dose Bevacizumab in Advanced Renal Carcinoma Patients Completed NCT00455975 Phase 2 Bevacizumab
42 Interferon Alfa (IFN-Alpha-1b) in Renal Cancer With Metastatic Kidney Cancer Completed NCT00278174 Phase 2
43 Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer Completed NCT00392821 Phase 1, Phase 2 Sorafenib;RAD001
44 Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer Completed NCT01158222 Phase 2 sunitinib malate
45 Rotating Pazopanib and Everolimus to Avoid Resistance Completed NCT01408004 Phase 2 Pazopanib;Everolimus;Pazopanib;Everolimus;Everolimus;Pazopanib
46 IMA901 in Advanced Renal Cell Carcinoma Patients With Measurable Disease Completed NCT00523159 Phase 2 Endoxana, IMA901, Leukine;IMA901 and Leukine
47 Bryostatin 1 In Treating Patients With Progressive Kidney Cancer Completed NCT00005056 Phase 2 bryostatin 1
48 Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer Completed NCT00719264 Phase 2 RAD001(everolimus);interferon alfa-2a;bevacizumab
49 A Study of RO4929097 in Patients With Advanced Renal Cell Carcinoma That Have Failed Vascular Endothelial Growth Factor (VEGF)/Vascular Endothelial Growth Factor Receptor (VEGFR) Therapy Completed NCT01141569 Phase 2 Gamma-Secretase Inhibitor RO4929097
50 Sunitinib Malate Before and After Surgery in Treating Patients With Previously Untreated Metastatic Kidney Cancer Completed NCT01024205 Phase 2 sunitinib malate

Search NIH Clinical Center for Clear Cell Renal Cell Carcinoma

Genetic Tests for Clear Cell Renal Cell Carcinoma

Genetic tests related to Clear Cell Renal Cell Carcinoma:

# Genetic test Affiliating Genes
1 Clear Cell Carcinoma of Kidney 29

Anatomical Context for Clear Cell Renal Cell Carcinoma

MalaCards organs/tissues related to Clear Cell Renal Cell Carcinoma:

41
Kidney, Endothelial, T Cells, Lung, Bone, Brain, Liver

Publications for Clear Cell Renal Cell Carcinoma

Articles related to Clear Cell Renal Cell Carcinoma:

(show top 50) (show all 1072)
# Title Authors Year
1
Involvement of transforming growth factor beta 1 in the transcriptional regulation of nicotinamide N-methyltransferase in clear cell renal cell carcinoma. ( 29974846 )
2018
2
Preclinical studies using miR-32-5p to suppress clear cell renal cell carcinoma metastasis via altering the miR-32-5p/TR4/HGF/Met signaling. ( 29396852 )
2018
3
Prognostic value of D-lactate dehydrogenase in patients with clear cell renal cell carcinoma. ( 29963157 )
2018
4
Influence of Contrast Administration on Computed Tomography-Based Analysis of Visceral Adipose and Skeletal Muscle Tissue in Clear Cell Renal Cell Carcinoma. ( 29350403 )
2018
5
Clear cell renal cell carcinoma: identifying PTEN expression on multiphasic MDCT. ( 29946925 )
2018
6
Genetic and metabolic hallmarks of clear cell renal cell carcinoma. ( 29959988 )
2018
7
SREBP1-driven lipid desaturation supports clear cell renal cell carcinoma growth through regulation of NF-I_B signaling. ( 29183723 )
2018
8
Up-regulation of SR-BI promotes progression and serves as a prognostic biomarker in clear cell renal cell carcinoma. ( 29357836 )
2018
9
Leukemia Inhibitory Factor Receptor Suppresses the Metastasis of Clear Cell Renal Cell Carcinoma Through Negative Regulation of the Yes-Associated Protein. ( 29902078 )
2018
10
FOXK2 suppresses the malignant phenotype and induces apoptosis through inhibition of EGFR in clear-cell renal cell carcinoma. ( 29368368 )
2018
11
Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma. ( 29368125 )
2018
12
Expression and clinical significance of COMPASS family of histone methyltransferases in clear cell renal cell carcinoma. ( 29944950 )
2018
13
DKC1 serves as a potential prognostic biomarker for human clear cell renal cell carcinoma and promotes its proliferation, migration and invasion via the NFa89I_B pathway. ( 29901172 )
2018
14
Potential impact of PD-L1 (SP-142) immunohistochemical heterogeneity in clear cell renal cell carcinoma immunotherapy. ( 29910061 )
2018
15
Evaluation and prognostic significance of manganese superoxide dismutase in clear cell renal cell carcinoma. ( 29935195 )
2018
16
Long noncoding RNA lung cancer associated transcript 1 promotes proliferation and invasion of clear cell renal cell carcinoma cells by negatively regulating miR-495-3p. ( 29932248 )
2018
17
Prognostic impact of concomitant loss of PBRM1 and BAP1 protein expression in early stages of clear cell renal cell carcinoma. ( 29426696 )
2018
18
Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma. ( 29378660 )
2018
19
Pathological Bases and Clinical Impact of Intratumor Heterogeneity in Clear Cell Renal Cell Carcinoma. ( 29374850 )
2018
20
Downregulation of microRNA-1274a induces cell apoptosis through regulation of BMPR1B in clear cell renal cell carcinoma. ( 29192325 )
2018
21
A Multicenter Phase II Trial of Axitinib in Patients With Recurrent or Metastatic Non-clear-cell Renal Cell Carcinoma Who Had Failed Prior Treatment With Temsirolimus. ( 29903415 )
2018
22
Ultrasound Molecular Imaging of VEGFR-2 in Clear-Cell Renal Cell Carcinoma Tracks Disease Response to Antiangiogenic and Notch-Inhibition Therapy. ( 29290798 )
2018
23
MicroRNA-19a and microRNA-19b promote the malignancy of clear cell renal cell carcinoma through targeting the tumor suppressor RhoB. ( 29474434 )
2018
24
Study on the mechanism behind lncRNA MEG3 affecting clear cell renal cell carcinoma by regulating miR-7/RASL11B signaling. ( 29968912 )
2018
25
p53I^: a new prognostic marker for patients with clear-cell renal cell carcinoma from 5.3 years of median followup. ( 29346503 )
2018
26
PBRM1 and VHL expression correlate in human clear cell renal cell carcinoma with differential association with patient's overall survival. ( 29169846 )
2018
27
Differentiation between pancreatic metastases from clear cell renal cell carcinoma and pancreatic neuroendocrine tumor using double-echo chemical shift imaging. ( 29500651 )
2018
28
Downregulation of long non-coding RNA ENSG00000241684 is associated with poor prognosis in advanced clear cell renal cell carcinoma. ( 29433989 )
2018
29
PPARI^ is dispensable for clear cell renal cell carcinoma progression. ( 29866440 )
2018
30
Architectural Patterns are a Relevant Morphologic Grading System for Clear Cell Renal Cell Carcinoma Prognosis Assessment: Comparisons With WHO/ISUP Grade and Integrated Staging Systems. ( 29356723 )
2018
31
Upregulated immune checkpoint HHLA2 in clear cell renal cell carcinoma: a novel prognostic biomarker and potential therapeutic target. ( 29967134 )
2018
32
The glutathione redox system is essential to prevent ferroptosis caused by impaired lipid metabolism in clear cell renal cell carcinoma. ( 29872221 )
2018
33
Decreased Expression of SATB2 Associates with Tumor Growth and Predicts Worse Outcome in Patients with Clear Cell Renal Cell Carcinoma. ( 29374710 )
2018
34
Follistatin-like protein 1 plays a tumor suppressor role in clear-cell renal cell carcinoma. ( 29357946 )
2018
35
Clinical utility of the S3-score for molecular prediction of outcome in non-metastatic and metastatic clear cell renal cell carcinoma. ( 29973214 )
2018
36
The prognostic significance of nuclear expression of PHF2 and C/EBPI+ in clear cell renal cell carcinoma with consideration of adipogenic metabolic evolution. ( 29416602 )
2018
37
Age-dependent prognostic value of body mass index for non-metastatic clear cell renal cell carcinoma: A large multicenter retrospective analysis. ( 29949668 )
2018
38
Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies. ( 29967214 )
2018
39
MiR-200c-3p inhibits cell migration and invasion of clear cell renal cell carcinoma via regulating SLC6A1. ( 29394133 )
2018
40
Identification of metabolism-associated genes and pathways involved in different stages of clear cell renal cell carcinoma. ( 29434939 )
2018
41
TR4 nuclear receptor promotes clear cell renal cell carcinoma (ccRCC) vasculogenic mimicry (VM) formation and metastasis via altering the miR490-3p/vimentin signals. ( 29973687 )
2018
42
Re: "Sex-Specific Prognostic Significance of Obesity in Nonmetastatic Clear-Cell Renal-Cell Carcinoma in Korea". ( 29958194 )
2018
43
The Oncogenic Role of COL23A1 in Clear Cell Renal Cell Carcinoma. ( 28852123 )
2017
44
The putative tumor suppressor microRNA-30a-5p modulates clear cell renal cell carcinoma aggressiveness through repression of ZEB2. ( 28569782 )
2017
45
Prognostic Value of the VHL, HIF-1I+, and VEGF Signaling Pathway and Associated MAPK (ERK1/2 and ERK5) Pathways in Clear-Cell Renal Cell Carcinoma. A Long-Term Study. ( 28624320 )
2017
46
Downregulation of a novel long non-coding RNA, LOC389332, is associated with poor prognosis and tumor progression in clear cell renal cell carcinoma. ( 28450954 )
2017
47
High NUCB2 expression level represents an independent negative prognostic factor in Chinese cohorts of non-metastatic clear cell renal cell carcinoma patients. ( 27806328 )
2017
48
Reduced expression of E-cadherin and increased sialylation level in clear cell renal cell carcinoma. ( 28742884 )
2017
49
Lysophosphatidylcholine acyltransferase 1 upregulation and concomitant phospholipid alterations in clear cell renal cell carcinoma. ( 28494778 )
2017
50
Recognizing the Continuous Nature of Expression Heterogeneity and Clinical Outcomes in Clear Cell Renal Cell Carcinoma. ( 28779136 )
2017

Variations for Clear Cell Renal Cell Carcinoma

ClinVar genetic disease variations for Clear Cell Renal Cell Carcinoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 OGG1 NM_016828.2(OGG1): c.137G> A (p.Arg46Gln) single nucleotide variant Pathogenic rs104893751 GRCh37 Chromosome 3, 9792107: 9792107
2 OGG1 NM_016828.2(OGG1): c.137G> A (p.Arg46Gln) single nucleotide variant Pathogenic rs104893751 GRCh38 Chromosome 3, 9750423: 9750423
3 HNF1A NM_000545.6(HNF1A): c.872dupC (p.Gly292Argfs) duplication Pathogenic rs587776825 GRCh37 Chromosome 12, 121432125: 121432125
4 HNF1A NM_000545.6(HNF1A): c.872dupC (p.Gly292Argfs) duplication Pathogenic rs587776825 GRCh38 Chromosome 12, 120994322: 120994322
5 PBRM1 NM_018313.4(PBRM1): c.3923_3930delATAGTGAG (p.Asp1308Valfs) deletion Pathogenic rs864321679 GRCh37 Chromosome 3, 52597380: 52597387
6 PBRM1 NM_018313.4(PBRM1): c.3923_3930delATAGTGAG (p.Asp1308Valfs) deletion Pathogenic rs864321679 GRCh38 Chromosome 3, 52563364: 52563371

Cosmic variations for Clear Cell Renal Cell Carcinoma:

9
(show top 50) (show all 2130)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM25676 VHL kidney,NS,carcinoma,renal cell c.485G>T p.C162F 3:10149808-10149808 32
2 COSM27269 UMPS kidney,NS,carcinoma,renal cell c.528G>A p.L176L 3:124737785-124737785 32
3 COSM30474 TRIO kidney,NS,carcinoma,renal cell c.9008A>G p.N3003S 5:14508136-14508136 32
4 COSM26594 RNF144A kidney,NS,carcinoma,renal cell c.410C>T p.A137V 2:7020581-7020581 32
5 COSM26987 RGS7 kidney,NS,carcinoma,renal cell c.169T>C p.F57L 1:241098672-241098672 32
6 COSM26614 RABGAP1 kidney,NS,carcinoma,renal cell c.1533T>A p.H511Q 9:123020414-123020414 32
7 COSM30530 PTPN22 kidney,NS,carcinoma,renal cell c.209G>C p.R70P 1:113859066-113859066 32
8 COSM27618 KMT2A kidney,NS,carcinoma,renal cell c.5711C>T p.A1904V 11:118497991-118497991 32
9 COSM30502 ITPR3 kidney,NS,carcinoma,renal cell c.4574G>T p.C1525F 6:33682621-33682621 32
10 COSM28415 DOCK1 kidney,NS,carcinoma,renal cell c.1306G>T p.D436Y 10:127023241-127023241 32
11 COSM30531 COPS4 kidney,NS,carcinoma,renal cell c.385G>C p.G129R 4:83049959-83049959 32
12 COSM25654 CDC5L kidney,NS,carcinoma,renal cell c.1196G>A p.R399Q 6:44419552-44419552 32
13 COSM30471 ARHGAP20 kidney,NS,carcinoma,renal cell c.1355A>G p.D452G 11:110586276-110586276 32
14 COSM6941466 XIAP kidney,NS,carcinoma,renal cell carcinoma c.563G>C p.G188A 23:123886225-123886225 31
15 COSM14312 VHL kidney,NS,carcinoma,renal cell carcinoma c.353T>C p.L118P 3:10146526-10146526 31
16 COSM17957 VHL kidney,NS,carcinoma,renal cell carcinoma c.292T>G p.Y98D 3:10142139-10142139 31
17 COSM14382 VHL kidney,NS,carcinoma,renal cell carcinoma c.245G>C p.R82P 3:10142092-10142092 31
18 COSM6957851 TSC2 kidney,NS,carcinoma,renal cell carcinoma c.541G>A p.V181M 16:2055461-2055461 31
19 COSM6942356 TSC1 kidney,NS,carcinoma,renal cell carcinoma c.2287C>T p.Q763* 9:132902709-132902709 31
20 COSM6963117 TSC1 kidney,NS,carcinoma,renal cell carcinoma c.1001C>A p.S334* 9:132911481-132911481 31
21 COSM29770 TSC1 kidney,NS,carcinoma,renal cell carcinoma c.508+1G>T p.? 9:132923347-132923347 31
22 COSM10656 TP53 kidney,NS,carcinoma,renal cell carcinoma c.742C>T p.R248W 17:7674221-7674221 31
23 COSM45243 TP53 kidney,NS,carcinoma,renal cell carcinoma c.374C>G p.T125R 17:7675995-7675995 31
24 COSM10647 TP53 kidney,NS,carcinoma,renal cell carcinoma c.404G>T p.C135F 17:7675208-7675208 31
25 COSM44310 TP53 kidney,NS,carcinoma,renal cell carcinoma c.738G>A p.M246I 17:7674225-7674225 31
26 COSM6922197 TP53 kidney,NS,carcinoma,renal cell carcinoma c.97-2A>C p.? 17:7676274-7676274 31
27 COSM45135 TP53 kidney,NS,carcinoma,renal cell carcinoma c.673-1G>T p.? 17:7674291-7674291 31
28 COSM6929752 TBX3 kidney,NS,carcinoma,renal cell carcinoma c.510G>T p.W170C 12:114681026-114681026 31
29 COSM6979493 STAG2 kidney,NS,carcinoma,renal cell carcinoma c.2096+1G>A p.? 23:124065947-124065947 31
30 COSM6975582 STAG2 kidney,NS,carcinoma,renal cell carcinoma c.1348A>T p.R450* 23:124057909-124057909 31
31 COSM6023628 STAG2 kidney,NS,carcinoma,renal cell carcinoma c.2860C>T p.R954C 23:124081464-124081464 31
32 COSM6963119 SPOP kidney,NS,carcinoma,renal cell carcinoma c.265T>G p.L89V 17:49619321-49619321 31
33 COSM6964939 SMARCB1 kidney,NS,carcinoma,renal cell carcinoma c.987-2A>T p.? 22:23833570-23833570 31
34 COSM989 SMARCB1 kidney,NS,carcinoma,renal cell carcinoma c.1130G>A p.R377H 22:23834152-23834152 31
35 COSM1266238 SMARCA4 kidney,NS,carcinoma,renal cell carcinoma c.3575G>A p.R1192H 19:11033318-11033318 31
36 COSM6947611 SETD2 kidney,NS,carcinoma,renal cell carcinoma c.863C>A p.S288* 3:47122264-47122264 31
37 COSM6975580 SETD2 kidney,NS,carcinoma,renal cell carcinoma c.4736C>G p.S1579* 3:47062211-47062211 31
38 COSM4118007 SETD2 kidney,NS,carcinoma,renal cell carcinoma c.3266G>A p.R1089Q 3:47106061-47106061 31
39 COSM4794860 SETD2 kidney,NS,carcinoma,renal cell carcinoma c.5922+1G>A p.? 3:47019759-47019759 31
40 COSM6925125 RBM10 kidney,NS,carcinoma,renal cell carcinoma c.179C>A p.S60* 23:47169476-47169476 31
41 COSM6922201 RBM10 kidney,NS,carcinoma,renal cell carcinoma c.299G>C p.G100A 23:47171125-47171125 31
42 COSM6947629 PTCH1 kidney,NS,carcinoma,renal cell carcinoma c.3616C>T p.R1206C 9:95449257-95449257 31
43 COSM6927541 PRKN kidney,NS,carcinoma,renal cell carcinoma c.629T>G p.F210C 6:161973407-161973407 31
44 COSM6913448 POLE kidney,NS,carcinoma,renal cell carcinoma c.4735C>T p.R1579C 12:132642723-132642723 31
45 COSM6972882 PMS1 kidney,NS,carcinoma,renal cell carcinoma c.572T>A p.V191E 2:189818170-189818170 31
46 COSM6923488 PIM1 kidney,NS,carcinoma,renal cell carcinoma c.101T>A p.L34Q 6:37170791-37170791 31
47 COSM6969911 PIK3CG kidney,NS,carcinoma,renal cell carcinoma c.2039T>A p.F680Y 7:106872580-106872580 31
48 COSM763 PIK3CA kidney,NS,carcinoma,renal cell carcinoma c.1633G>A p.E545K 3:179218303-179218303 31
49 COSM6921803 PIK3C2G kidney,NS,carcinoma,renal cell carcinoma c.3493T>C p.F1165L 12:18562728-18562728 31
50 COSM6922195 PIK3C2G kidney,NS,carcinoma,renal cell carcinoma c.1986G>C p.Q662H 12:18391235-18391235 31

Copy number variations for Clear Cell Renal Cell Carcinoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 135083 2 111395408 111435684 Copy number BUB1 Clear cell renal cell carcinoma
2 181389 4 120800000 123800000 Copy number MAD2L1 Clear cell renal cell carcinoma

Expression for Clear Cell Renal Cell Carcinoma

Search GEO for disease gene expression data for Clear Cell Renal Cell Carcinoma.

Pathways for Clear Cell Renal Cell Carcinoma

GO Terms for Clear Cell Renal Cell Carcinoma

Sources for Clear Cell Renal Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....